Is kidney injury from Cabozantinib reversible?

Reversible. Typical onset: Within weeks of starting therapy..

How should kidney function be monitored during Cabozantinib therapy?

Blood pressure weekly initially, then with each visit; Urine protein (dipstick/UPCR) before each cycle.

How can kidney injury from Cabozantinib be prevented?

Blood pressure optimization before and during therapy

Who is at higher risk of kidney injury from Cabozantinib?

Pre-existing hypertension; Baseline proteinuria or CKD; Diabetes.

Back to explorer

Printable monograph

VEGFR/MET TKI

Cabozantinib

Cabometyx · Cabo

VEGFR/MET TKI · approved 2012 · 10 citations

Up to date· through 2026

Deeply sourced7/9 · 6 signals

Met: 10 citations
Not met: 12+ references
Met: Accrued over 10+ years (span: 13y)
Met: Beyond single case reports
Met: High-impact journal
Met: Landmark reference
Met: Current through 2026
Not met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

A VEGFR/MET TKI whose antiangiogenic reach brings hypertension, proteinuria and occasional nephrotic-range injury.

ModerateVEGFR/MET multikinase inhibitor

Renal cell carcinomaHepatocellular carcinomaMedullary thyroid cancerDifferentiated thyroid cancer (refractory)

§01

Signature kidney injury

Signature lesion

Hypertension

Representative grade ≥3 incidence15%

Hypertension and proteinuria are common; in pivotal RCC trials (e.g., METEOR, CABOSUN) hypertension was among the most frequent adverse events with grade >=3 rates around 15-28%. Cabozantinib is one of the TKIs most often associated with proteinuria, with case reports of nephrotic syndrome. Reported rate: grade >=3 hypertension in 15% — Adults with advanced/metastatic clear-cell renal cell carcinoma previously treated with >=1 VEGFR tyrosine-kinase… (Choueiri 2016, PMID 27279544).Source: Nervo et al., Crit Rev Oncol Hematol 2021; METEOR (Choueiri, NEJM 2015)

Onset & rechallenge

Time to injurySubacute (~1–6 weeks)

Within weeks of starting therapy.

Distilled from: “Within weeks of starting therapy.”

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

Hypertension#1 · Signatureno population incidence denominator
Most common anti-angiogenic adverse event; significantly increased risk vs control (all-grade RR 5.48, 95% CI 3.76-7.99; high-grade RR 5.09) in a meta-analysis of 8 trials (n=1,514), with higher high-grade risk than sorafenib, sunitinib, vandetanib or pazopanib. PMID 27181268 (opens PubMed in a new tab)
Glomerular Injury / ProteinuriaSecondaryqualitative — no citable incidence
Damage to the filtration barrier — podocyte injury, FSGS and protein leak from VEGF and mTOR blockade.

Toxicity fingerprint

Tap a signature to trace where it strikes the nephron.

15%grade ≥3 incidence

SeverityModerate

ReversibilityReversible

Evidence10 citations

Nephron map

GlomerulusFiltration barrier (podocytes + endothelium)

Vasculature / EndotheliumGlomerular & peritubular capillaries

Hypertension

Raised blood pressure — archetypally on-target loss of endothelial nitric oxide from VEGF-pathway blockade, studied as a pharmacodynamic marker of drug exposure. Other agents raise it too: vascular effects of BCR-ABL, BTK and RET inhibitors and of copanlisib; abiraterone's mineralocorticoid excess; androgen suppression or blockade.

§03

Kidney injury

Deep diveVEGF-inhibitor thrombotic microangiopathyStarve a tumor of its blood supply and you also cut the survival signal podocytes whisper to the glomerular endothelium next door — the capillary tuft answers with thrombi, protein spilling into the urine, and a blood pressure that will not come down.

Mechanism of kidney injury

Inhibition of VEGFR2 signaling impairs glomerular endothelial and podocyte maintenance and reduces nitric-oxide-mediated vasodilation, producing hypertension, proteinuria and a podocytopathy (FSGS/minimal-change-like lesions); renal TMA can also occur with anti-VEGF-pathway agents. The added MET inhibition may further perturb podocyte HGF/MET survival signaling.

Clinical presentation

New or worsening hypertension with proteinuria; nephrotic-range proteinuria with edema in reported cases, and occasionally a creatinine rise.

Management

Antihypertensive therapy (ACE inhibitor/ARB favored); interrupt or dose-reduce per label for grade 3 hypertension or significant proteinuria and discontinue for nephrotic syndrome, hypertensive crisis or TMA. Abnormalities typically improve with dose modification or withdrawal.Lesion-level management framework

§ Receptor target map

Which kinases Cabozantinib blocks — and where the blockade reaches the kidney

5targeted

VEGFR2 is the target with documented renal consequences across every VEGFR TKI; multi-kinase breadth beyond it (PDGFR-β, FGFR, and off-target receptor kinases) adds further renal and hypertensive liability. Select a lit receptor for its renal consequence.

VEGFR family

VEGFR1VEGFR3

PDGFR

PDGFR-αPDGFR-β

Other receptor kinases

FGFREGFRFLT3CSF1RTIE2RAF-1/BRAF

VEGFR2 · renal target

Glomerular endothelial VEGFR2: loss of podocyte-derived paracrine VEGF signaling → fenestrae loss, nephrin downregulation, nitric-oxide depletion → hypertension, proteinuria, and thrombotic microangiopathy.

renal consequence (2)targetednot a target

Risk factors

Pre-existing hypertension
Baseline proteinuria or CKD
Diabetes

Prevention

Blood pressure optimization before and during therapy

Anticancer mechanism· how it treats cancer

Oral multikinase inhibitor of VEGFR2, MET, AXL, RET, KIT and others, simultaneously blocking angiogenesis and MET/AXL-driven tumor-cell signaling and invasion (the MET/AXL activity is thought to counter VEGFR-inhibitor escape). Used in renal cell carcinoma, hepatocellular carcinoma and medullary/differentiated thyroid cancer.

Note · Proteinuria signal is prominent within the TKI class (alongside lenvatinib); nephrotic presentations are case-level. Cabozantinib is also a feature in sequential-TKI proteinuria case series in thyroid cancer.

§04

Clinical depth

Renal dose adjustment

No dose adjustment for mild-to-moderate renal impairment; cabozantinib has not been studied in severe renal impairment or ESKD, so use is cautious there. It is hepatically metabolized (CYP3A4), and dose reduction is recommended for hepatic impairment.

Dialyzability & ESKD dosing

Highly protein-bound (~99.7%) and hepatically cleared, so it is not meaningfully dialyzable; no supplemental dosing rationale for HD, and data in dialysis patients are sparse.

Differential diagnosis

TKI podocytopathy (FSGS/MCD with proteinuria + hypertension) versus anti-VEGF-antibody TMA versus baseline diabetic/hypertensive nephropathy versus prerenal AKI. The MET-inhibitor component does not change the bedside differential, which rests on biopsy pattern and temporal association.

Monitoring

Blood pressure weekly initially, then with each visit
Urine protein (dipstick/UPCR) before each cycle

Key trials & series

METEOR phase III (cabozantinib vs everolimus in RCC) — hypertension a leading AE
CABOSUN and CELESTIAL (HCC) — proteinuria/hypertension safety signals

Clinical pearls

Cabozantinib and lenvatinib are the proteinuria heavyweights among VEGFR-TKIs.
Its dual VEGFR/MET activity may amplify podocyte injury beyond pure VEGFR blockade.
Sequential TKI exposure (lenvatinib then sorafenib then cabozantinib) can produce recurrent proteinuria — track urine protein across switches.

Beyond the kidney — non-renal toxicities· 4 organ systems

Class-level context for the major non-renal toxicities of the VEGFR/MET TKI class.

Vascular

Hypertension, VTE/ATE, bleeding, aneurysm

Hypertension, arterial/venous thrombosis, bleeding, impaired wound healing

Cardiac

Cardiomyopathy, QT, ischemia, myocarditis

LV dysfunction; QT (some TKIs)

Gastrointestinal

Diarrhea, colitis, mucositis, perforation

Diarrhea, perforation/fistula

Dermatologic

Rash, HFS, SJS/TEN, vitiligo

Hand-foot skin reaction

§05

References

7 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.

Evidence accrual

7 references · 2013–2026 · 1 since 2024

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

Case reports — ranked by strength· 3

Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.

CaseB · ModerateCabozantinib-induced renal thrombotic microangiopathy.La Manna G et al. · Nephrology (Carlton) 2018 · PMID 29250919Biopsy-documented case of renal thrombotic microangiopathy caused by cabozantinib.CaseC · LimitedAtypical Posterior Reversible Encephalopathy Syndrome due to Oral Tyrosine Kinase Inhibitor Cabozantinib: First Case Report.Patwari A et al. · Case Rep Oncol 2020 · PMID 32999665Cabozantinib-induced severe hypertension precipitating posterior reversible encephalopathy syndrome.CaseC · LimitedCabozantinib-induced hand-foot skin reaction with subungual splinter hemorrhages and hypertension: a possible association with inhibition of the vascular endothelial growth factor signaling pathway.Cho YT et al. · Eur J Dermatol 2013 · PMID 23518371Case documenting cabozantinib-induced hypertension via VEGF pathway inhibition.

Conference abstracts & journal reports· 1 non-PubMed

Non-PubMed sources — conference abstracts (e.g. ASN Kidney Week, badged Abstract) and case reports from non-indexed field journals (e.g. Journal of Onco-Nephrology, badged Journal). Included for completeness; weigh below peer-reviewed PubMed citations.

AbstractChronic Limited Renal Thrombotic Microangiopathy and Podocytopathy Secondary to CabozantinibASN Kidney Week 2024 2024 · Abstract PUB324Biopsy-proven chronic renal-limited TMA with ultrastructural podocytopathy presenting as worsening nephrotic-range proteinuria in an HCC patient; attributed to cabozantinib's anti-angiogenic disruption of glomerular vascular integrity, prompting a switch of regimen.

FDA label — boxed warning & renal dosing· renal impairment

Quoted verbatim from this agent's current FDA label (Oct 2025) — not paraphrased or interpreted. Full label on DailyMed .

Renal impairment — from the label

No dosage adjustment is recommended in patients with mild or moderate renal impairment. There is no experience with CABOMETYX in patients with severe renal impairment [see Clinical Pharmacology (12.3) ] .

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 47,766 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.

FAERS reported renal phenotypes· 4 signals

Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-10-01.

What reporting says about this profile's documented lesions

Glomerular Injury / Proteinuriacorroborated · ROR 9.22 — on the terms that name the lesion (ROR 3.24)
Hypertensioncorroborated · ROR 6.65 — on the terms that name the lesion (ROR 3.89)

Glomerular Injury / Proteinuria

ROR 9.2295% CI 8.49–10.00· 593 reports

Hypertension

ROR 6.6595% CI 6.46–6.85· 5,235 reports

SIADH / Hyponatremia

ROR 2.1195% CI 1.91–2.33· 384 reports

Electrolyte Disturbance

ROR 1.7595% CI 1.63–1.89· 757 reports

FAERS outcomes & reporting trend· 11.2% of reports w/ death · 19.1% w/ hospitalization

11.2%

Reported with a death outcome

5,351 of 47,766 reports

19.1%

Reported with hospitalization

9,123 of 47,766 reports

Reports per year

Yearly FAERS report volume · most recent year is partial.

FAERS adverse-event signal — all organ systems· 8 systems · 47,766 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-10-01.

Disproportionality (acute kidney injury):ROR 0.6695% CI 0.58–0.75· 230 AKI reports ·AKI is reported less often than for other drugs (CI entirely below 1) — no disproportionate signal.

Gastrointestinal

Diarrhoea9,449Nausea4,989Stomatitis2,898Constipation2,377Vomiting2,226

General / constitutional

Fatigue7,696Weight Decreased3,038Asthenia2,148Malaise1,797Pain1,233

Skin

Palmar-Plantar Erythrodysaesthesia Syndrome3,113Blister2,097Rash1,833Dry Skin1,309Pruritus1,203

Vascular

Blood Pressure Increased3,196Hypertension1,885

Metabolic & electrolyte

Decreased Appetite4,620

Nervous system

Taste Disorder1,992

Musculoskeletal

Pain In Extremity1,786

Respiratory

Dysphonia1,408

Guidelines & consensus· 17

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

KDIGOManagement of Blood Pressure in Patients With Chronic Kidney Disease Not Receiving Dialysis: Synopsis of the 2021 KDIGO Clinical Practice GuidelineAnn Intern Med 2021 · PMID 34152826Recommends standardized office BP measurement and a target systolic BP <120 mm Hg for most CKD patients, with RAAS inhibitors first-line when albuminuria is present — the BP-management basis for anti-VEGF/TKI-induced hypertension and proteinuria.ESC2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)Eur Heart J 2022 · PMID 36017568For VEGF/VEGFR inhibitors, perform baseline cardiovascular risk assessment, monitor blood pressure (weekly during the first cycle, then regularly) and treat to a target <140/90 mmHg with ACE inhibitors/ARBs and dihydropyridine calcium-channel blockers; manage VEGFi-associated hypertension and proteinuria with interruption/dose modification when severe.ESCEuropean Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatmentEur Heart J Qual Care Clin Outcomes 2022 · PMID 36316010Adherence quality indicators require documented baseline cardiovascular risk assessment and structured monitoring of cardiovascular complications (including hypertension) during cancer therapy such as VEGF-pathway inhibitors.UK Consensus PanelUsing bevacizumab to treat metastatic cancer: UK consensus guidelinesBr J Hosp Med (Lond) 2010 · PMID 21135762Assess and monitor blood pressure and proteinuria during bevacizumab therapy; treat emergent hypertension to standard targets and interrupt/discontinue the drug for uncontrolled hypertension, nephrotic-range proteinuria or other severe vascular toxicity.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Cabozantinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.

Phenotype-similar agents· the numbered markers on the map above

Lenvatinib

Lenvima · VEGFR TKI

Profile

Highest-ranked TKI for hypertension; proteinuria.

HTNGLOM

Moderate#1 · 100% phenotype match

Regorafenib

Stivarga · VEGFR TKI

Profile

Hypertension and proteinuria.

HTNGLOM

Moderate#2 · 100% phenotype match

Tivozanib

Fotivda · VEGFR TKI

Profile

Hypertension and proteinuria in RCC.

HTNGLOM

Moderate#3 · 100% phenotype match

Ziv-aflibercept

Zaltrap · VEGF trap

Profile

Hypertension and proteinuria like bevacizumab.

HTNGLOMTMA

Moderate#4 · 84% phenotype match

Bevacizumab

Avastin · Anti-VEGF antibody

Profile

Proteinuria, hypertension, glomerular TMA.

GLOMHTNTMA

Moderate#5 · 84% phenotype match

Ramucirumab

Cyramza · Anti-VEGFR2 antibody

Profile

Hypertension and proteinuria, class effect.

HTNGLOMTMA

Moderate#6 · 84% phenotype match

Compare Cabozantinib with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across Anti-angiogenic (VEGF)

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile.

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.

Who studies this

The leading contributors to Cabozantinib’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Cabozantinib; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.

Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 25 clinical records among all 30 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.